Kenneth R Carson1,2, Steven M Horwitz3, Lauren C Pinter-Brown4, Steven T Rosen5, Barbara Pro6, Eric D Hsi7, Massimo Federico8, Christian Gisselbrecht9, Marc Schwartz10, Lisa A Bellm10, Mark A Acosta11, Andrei R Shustov12, Ranjana H Advani13, Tatyana A Feldman14, Mary Jo Lechowicz15, Sonali M Smith16, Frederick Lansigan17, Anil Tulpule18, Michael D Craig19, John P Greer20, Brad S Kahl2, Joseph W Leach21, Neil Morganstein22, Carla Casulo23, Steven I Park24, Francine M Foss25. 1. Research Service, St Louis Veterans Affairs Medical Center, St. Louis, Missouri. 2. Department of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. 3. Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Medicine, University of California at Irvine, Irvine, California. 5. Provost and Chief Scientific Officer, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California. 6. Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. 7. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio. 8. Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy. 9. Department of Hematology-Oncology, Hôpital Saint Louis, Paris, France. 10. MedNet Solutions, Minnetonka, Minnesota. 11. Research and Development, Spectrum Pharmaceuticals Inc, Irvine, California. 12. Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington. 13. Department of Medicine, Stanford University Medical Center, Stanford, California. 14. Department of Hematology/Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. 15. Department of Hematology and Oncology, Emory University, Atlanta, Georgia. 16. Department of Medicine, University of Chicago, Chicago, Illinois. 17. Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, New Hampshire. 18. Department of Medicine, University of Southern California, Los Angeles, California. 19. Department of Medicine, West Virginia University, Morgantown, West Virginia. 20. Department of Hematology, Vanderbilt University, Nashville, Tennessee. 21. Minnesota Oncology, Virginia Piper Cancer Institute, Minneapolis, Minnesota. 22. Overlook Medical Center, Summit, New Jersey. 23. Department of Medicine, University of Rochester, Rochester, New York. 24. Department of Internal Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 25. Department of Medical Oncology, Yale University, New Haven, Connecticut.
Abstract
BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P = .03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P = .09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174-1183.
BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided. RESULTS: Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P = .03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P = .09]). CONCLUSIONS: To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174-1183.
Authors: Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz Journal: Ann Intern Med Date: 2009-06-30 Impact factor: 25.391
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: P Pautier; A Devidas; A Delmer; H Dombret; L Sutton; J M Zini; G Nedelec; T Molina; J P Marolleau; P Brice Journal: Leuk Lymphoma Date: 1999-02
Authors: Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Nathalie Mourad; Nicolas Mounier; Josette Brière; Emmanuel Raffoux; Alain Delmer; Alfred Feller; Chris J L M Meijer; Jean-François Emile; Réda Bouabdallah; André Bosly; Jacques Diebold; Corinne Haioun; Bertrand Coiffier; Christian Gisselbrecht; Philippe Gaulard Journal: Blood Date: 2008-02-21 Impact factor: 22.113
Authors: J S Abramson; T Feldman; A R Kroll-Desrosiers; L S Muffly; E Winer; C R Flowers; F Lansigan; C Nabhan; L J Nastoupil; R Nath; A Goy; J J Castillo; D Jagadeesh; B Woda; S T Rosen; S M Smith; A M Evens Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: R Briski; A L Feldman; N G Bailey; M S Lim; K Ristow; T M Habermann; W R Macon; D J Inwards; J P Colgan; G S Nowakowski; M S Kaminski; T E Witzig; S M Ansell; R A Wilcox Journal: Blood Cancer J Date: 2014-05-30 Impact factor: 11.037
Authors: Robert N Stuver; Niloufer Khan; Marc Schwartz; Mark Acosta; Massimo Federico; Christian Gisselbrecht; Steven M Horwitz; Frederik Lansigan; Lauren C Pinter-Brown; Barbara Pro; Andrei R Shustov; Francine M Foss; Salvia Jain Journal: Am J Hematol Date: 2019-04-09 Impact factor: 10.047
Authors: Steven I Park; Steven M Horwitz; Francine M Foss; Lauren C Pinter-Brown; Kenneth R Carson; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark Acosta; Ranjana H Advani; Tatyana Feldman; Mary Jo Lechowicz; Sonali M Smith; Frederick Lansigan; Anil Tulpule; Michael D Craig; John P Greer; Brad S Kahl; Joseph W Leach; Neil Morganstein; Carla Casulo; Andrei R Shustov Journal: Cancer Date: 2019-01-29 Impact factor: 6.860
Authors: Andrei Shustov; Maria Elena Cabrera; Monica Civallero; Monica Bellei; Young Hyeh Ko; Martina Manni; Tetiana Skrypets; Steven M Horwitz; Carmino Antonio De Souza; John A Radford; Sabela Bobillo; Maria Virginia Prates; Andrés J M Ferreri; Carlos Chiattone; Michele Spina; Julie M Vose; Annalisa Chiappella; Daniele Laszlo; Dario Marino; Caterina Stelitano; Massimo Federico Journal: Blood Adv Date: 2021-02-09
Authors: Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper Journal: Lancet Date: 2018-12-04 Impact factor: 79.321
Authors: Ranjana H Advani; Tetiana Skrypets; Monica Civallero; Michael A Spinner; Martina Manni; Won Seog Kim; Andrei R Shustov; Steven M Horwitz; Felicitas Hitz; Maria Elena Cabrera; Ivan Dlouhy; José Vassallo; Stefano A Pileri; Giorgio Inghirami; Silvia Montoto; Umberto Vitolo; John Radford; Julie M Vose; Massimo Federico Journal: Blood Date: 2021-07-22 Impact factor: 25.476
Authors: Frederick Lansigan; Steven M Horwitz; Lauren C Pinter-Brown; Kenneth R Carson; Andrei R Shustov; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark Acosta; Francine M Foss Journal: Clin Lymphoma Myeloma Leuk Date: 2020-05-11